Additionally, fresolimumab was well tolerated and used in participants with osteogenesis imperfecta (OI) type IV, as well as a TGF-β-neutralizing antibody (Song et al., 2022). This evidence concerns the gene TGFB1 and osteogenesis imperfecta.